选择性WEE1抑制剂阿泽诺塞替布在临床前模型中与KRASG12C抑制剂显示出协同抗肿瘤活性。
The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.
作者信息
Jameson Nathan M, Kim Daehwan, Lee Catherine, Skrable Blake, Shea Alexandra, Guo Xiao, Izadi Hooman, Abed Mona, Harismendy Olivier, Ma Jianhui, Kim Doris S, Lackner Mark R
机构信息
Zentalis Pharmaceuticals, Inc., San Diego, California.
出版信息
Cancer Res Commun. 2025 Feb 1;5(2):240-252. doi: 10.1158/2767-9764.CRC-24-0411.
Abstract
Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.
摘要
对KRASG12C抑制剂的耐药性是一个日益严重的临床问题。在氮杂塞替布与多种KRASG12C抑制剂之间观察到的协同相互作用可能会产生更深且更持久的反应。
Zotero 插件